Solar energy is a vast renewable energy source, but uncertainty in the demand and supply of energy due to various geographical regions raises a question mark. Therefore, the present manuscript includes a review to overcome this uncertainty by utilizing various thermal energy storage systems. Phase change material is the most preferred thermal energy storage system because of its high-energy storage density. The low thermal conductivity is the critical problem in phase change material that can be overcome by integrating metallic foam, carbon fiber, and metallic fins in the phase change material container. The inclusion of metallic foam limited to 0.1-3% of the Phase change material (PCM) weight leads to a slight change in thermal conductivity but a high cost. It was also seen that the addition of carbon 0.1 to 9% of the PCM weight could improve the performance of PCM. The inclusion of a metallic fin improves the thermal conductivity with the various shapes and sizes of the fin. It is found that metallic foam composites have better performance than carbon composite and metallic fin inclusion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11356-022-24552-x | DOI Listing |
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFJ Clin Psychiatry
January 2025
Division of Pharmacotherapy and Translational Science, College of Pharmacy, University of Texas at Austin, San Antonio, Texas.
To evaluate weight change with a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine by pooling data across clinical studies. This study was an individual patient data (IPD) meta-analysis of clinical trial data. EMBASE, MEDLINE, and PsycInfo were searched for randomized clinical trials (≥12 weeks) in adults with schizophrenia or bipolar I disorder in which weight change from baseline was the primary or secondary end point.
View Article and Find Full Text PDFCent Eur J Public Health
December 2024
Department of Radiology, AGEL Hospital, Levoca, Slovak Republic.
Objectives: Many studies draw attention to the negative consequences of the pandemic or lockdown on the well-being and lifestyle of different sections of the population. This study considers whether changes occurred in dietary regime and level of physical activity during three periods - before the pandemic, during the lockdown, and during the present in older Slovak adults. We also investigate whether individual weights changed during the pandemic.
View Article and Find Full Text PDFClin Drug Investig
January 2025
Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Background: Anti-obesity medications are recommended for patients who do not achieve and maintain weight loss despite lifestyle interventions. S-309309 is a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 being developed as a treatment for obesity.
Objective: The objective of the study was to investigate the safety, clinical pharmacology, pharmacokinetics and pharmacodynamic biomarker of S-309309.
Clin Cancer Res
January 2025
The Wistar Institute, Philadelphia, PA, United States.
Purpose: A first-in-human phase one study was conducted in nasopharyngeal carcinoma (NPC) patients to assess the safety and tolerability of VK-2019, a small molecule selective inhibitor of Epstein-Barr virus Nuclear Antigen 1 (EBNA1).
Patients And Methods: Pharmacokinetic and pharmacodynamic studies, including circulating tumor EBV DNA plasma levels, were performed. Twenty-three patients received VK-2019 orally once daily at doses ranging from 60 to 1800 mg using an accelerated titration design, with cohort expansion at 1800 mg.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!